Benzinga | May 28, 2021 09:22AM EDT

Credit Suisse Maintains Outperform on Ascendis Pharma, Raises Price Target to $178

Credit Suisse analyst Tiago Fauth maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $176 to $178.